VetImmune® statement on COVID-19

March 13, 2020

To our customers, cat guardians, and veterinary professionals,

With the Coronavirus (COVID-19) being a dominant topic in the news and workplaces, we want to provide you, with an update on how VetImmune® is ensuring our ability to meet your Polyprenyl Immunostimulant™ needs during this challenging time.

As you know, VetImmune® has been providing veterinary community with Polyprenyl Immunostimulant™ the only treatment of Feline Viral Rhinotracheitis (FVR) licensed by the USDA. Veterinarians in 41 different countries are using Polyprenyl Immunostimulant™ for treating of acute and chronic forms of FVR and also experimenting with treatment of dry form of Feline Infectious Peritonitis (FIP) based on  Dr.Legendre’s 15+ years research and trials with Polyprenyl Immunostimulant™  1, 2, 3  

Here is how we are managing this situation:

VetImmune® has contingencies in place to maintain an uninterrupted supply of Polyprenyl Immunostimulant™ domestically and overseas.

Our exclusive supplier Sass & Sass, Inc. is producing Polyprenyl Immunostimulant™ entirely in the US, at their USDA licensed facility, from 100% US sourced raw materials. Sass & Sass, Inc. informed us that they have sufficient resources in the US to continue supplying Polyprenyl Immunostimulant™ for at least a year and a work-in-process for a rapid production of 2+ years of Polyprenyl Immunostimulant™ inventory with all needed supplies available in-house.

Our international customers may purchase our product labeled as VetImmune-PI from its distributor in Czechia (European Union) Panda Plus S.R.O.  and smaller distribution sources in South East Asia.

Thank you for your commitment to VetImmune®.

We look forward to our ongoing business and appreciate the trust you place in our company.